Latest News Archive
Please select Category, Year, and then Month to display items
08 August 2023
|
Story EDZANI NEPHALELA
|
Photo EDZANI NEPHALELA
Mbulelo Aven Jafta, Xhariep Municipality Corporate Services Director, and Dr Engela van Staden, Deputy Vice-Chancellor: Academic at the UFS, sign a memorandum of understanding to enrich various communities in the Xhariep Municipality areas through leadership training.
The University of the Free State (UFS) has signed a memorandum of understanding with the South African Local Government Association (SALGA) and the Xhariep Municipality that is aimed at positively impacting communities through strategic partnerships. The organisations plan for their collaboration to make a significant difference by training 35 of their employees via the UFS Business School – 15 will undertake the Foundation Skills Short Learning Programme, and 20 the Bachelor’s degree in Management Leadership.
This joint effort will equip these employees with essential skills and knowledge and empower them to carry out their responsibilities efficiently and effectively. Rooted in the UFS’s Vision 130, this initiative fosters positive change within the community by enhancing social justice and innovation.
Dr Engela van Staden, Deputy Vice-Chancellor: Academic at the UFS, emphasised the university's dedication to human resource development and empowering individuals. “We were very excited when we got this engagement with you, and I hope it will be fruitful for you, because that’s the intention. We are also reaching out to other municipalities because we are doing it for our country, and the sooner we do it, the better the services you will deliver to people.”
Xhariep Municipality expressed gratitude for the collaboration, recognising its significance in empowering its employees. Mbulelo Aven Jafta, Corporate Services Director at the municipality, thanked the university for accepting the partnership. “As a municipality, we are interested in capacitating our employees to perform their duties optimally. It is through these partnerships that we reach our intended targets. This is the first two projects, and many more will be coming as our partnership progresses, and we intend to use this opportunity to the best of our abilities.”
Jafta said that such partnerships encourage a more interconnected and interdependent world. “As organisations work towards common goals, they create a ripple effect that can lead to a brighter and more promising future and play a vital role in shaping a positive and sustainable future.”
UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08
The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.
The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.
The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.
“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.
“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.
According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.
The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.
According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.
The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.
Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004